These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 9869577

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR, Nicolau DP, Onyeji CO, Nightingale CH.
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
    Crandon JL, Bulik CC, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
    den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK, Kuti JL, Nicolau DP.
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.
    Ambrose PG, Owens RC, Garvey MJ, Jones RN.
    J Antimicrob Chemother; 2002 Mar; 49(3):445-53. PubMed ID: 11864944
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM, Abdelraouf K, Nicolau DP.
    J Antimicrob Chemother; 2020 Jan 01; 75(1):149-155. PubMed ID: 31641765
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 01; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2017 Dec 01; 61(12):. PubMed ID: 28993331
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ, Grove ME, Kiel PJ, O'Donnell JN, Whited LK, Rose DT, Jones DR, Scheetz MH.
    Int J Antimicrob Agents; 2017 Sep 01; 50(3):482-486. PubMed ID: 28668694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.